Ignite Creation Date:
2024-05-06 @ 4:28 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04995419
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-27
First Post:
2021-08-02
Brief Title:
A Study to Evaluate Enfortumab Vedotin ASG-22CE in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 PD 1 Programmed Death Ligand-1 PD-L1 Inhibitor Therapy
Sponsor:
Organization:
Astellas Pharma Inc